Cryptococcal meningoencephalitis : time for action
Copyright © 2021 Elsevier Ltd. All rights reserved..
Cryptococcal meningoencephalitis was first described over a century ago. This fungal infection is preventable and treatable yet continues to be associated with excessive morbidity and mortality. The largest burden of disease resides in people living with HIV in low-income and middle-income countries. In this group, mortality with the best antifungal induction regimen (7 days of amphotericin B deoxycholate [1·0 mg/kg per day] and flucytosine [100·0 mg/kg per day]) in a clinical trial setting was 24% at 10 weeks. The world is now at an inflection point in terms of recognition, research, and action to address the burden of morbidity and mortality from cryptococcal meningoencephalitis. However, the scope of interventional programmes needs to increase, with particular attention to implementation science that is specific to individual countries. This Review summarises causes of excessive mortality, interventions with proven survival benefit, and gaps in knowledge and practice that contribute to the ongoing high death toll from cryptococcal meningoencephalitis. TRANSLATIONS: For the Vietnamese and Chichewa translations of the abstract see Supplementary Materials section.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 21(2021), 9 vom: 03. Sept., Seite e259-e271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stott, Katharine Elizabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.09.2021 Date Revised 21.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(20)30771-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324271891 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324271891 | ||
| 003 | DE-627 | ||
| 005 | 20240222091111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(20)30771-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM324271891 | ||
| 035 | |a (NLM)33872594 | ||
| 035 | |a (PII)S1473-3099(20)30771-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stott, Katharine Elizabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cryptococcal meningoencephalitis |b time for action |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2021 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Cryptococcal meningoencephalitis was first described over a century ago. This fungal infection is preventable and treatable yet continues to be associated with excessive morbidity and mortality. The largest burden of disease resides in people living with HIV in low-income and middle-income countries. In this group, mortality with the best antifungal induction regimen (7 days of amphotericin B deoxycholate [1·0 mg/kg per day] and flucytosine [100·0 mg/kg per day]) in a clinical trial setting was 24% at 10 weeks. The world is now at an inflection point in terms of recognition, research, and action to address the burden of morbidity and mortality from cryptococcal meningoencephalitis. However, the scope of interventional programmes needs to increase, with particular attention to implementation science that is specific to individual countries. This Review summarises causes of excessive mortality, interventions with proven survival benefit, and gaps in knowledge and practice that contribute to the ongoing high death toll from cryptococcal meningoencephalitis. TRANSLATIONS: For the Vietnamese and Chichewa translations of the abstract see Supplementary Materials section | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Deoxycholic Acid |2 NLM | |
| 650 | 7 | |a 005990WHZZ |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a amphotericin B, deoxycholate drug combination |2 NLM | |
| 650 | 7 | |a 87687-70-5 |2 NLM | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Flucytosine |2 NLM | |
| 650 | 7 | |a D83282DT06 |2 NLM | |
| 700 | 1 | |a Loyse, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Jarvis, Joe N |e verfasserin |4 aut | |
| 700 | 1 | |a Alufandika, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Thomas Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Mwandumba, Henry C |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Jeremy N |e verfasserin |4 aut | |
| 700 | 1 | |a Lalloo, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Bicanic, Tihana |e verfasserin |4 aut | |
| 700 | 1 | |a Perfect, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Hope, William |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 21(2021), 9 vom: 03. Sept., Seite e259-e271 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:9 |g day:03 |g month:09 |g pages:e259-e271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(20)30771-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 9 |b 03 |c 09 |h e259-e271 | ||